Logo

International Task Force for Prevention of
Coronary Heart Disease


CORONARY HEART DISEASE: REDUCING THE RISK

2.5 The risk review

After the patient has been assessed as detailed in sections 2.1 (Personal and family history) to 2.3 (Biochemical and laboratory risk factors), his/her risk of developing CHD can be estimated. This assessment is of central importance, since it determines the goals of therapy and thus the intensity of treatment. As in all areas of medical practice, the risk review implies the clinical judgement of the individual patient and his/her unique circumstances. Today the doctor can draw on a body of evidence from epidemiological studies and from prospective clinical trials to inform clinical assessment and to guide therapeutic decision-making. Both approaches may be used in complementary fashion to assess the individual risk and to decide on the correct modality and intensity of treatment.
The goal of risk assessment is to determine an appropriate type and intensity of treatment. In the case of lipid risk fac-tors, this implies deciding how intensive a diet is needed, whether a drug is required and if so at what dosage, and what target levels to aim for. This may be achieved by judging whether the patient is at average risk or whether she/he falls into one of the three grades of increased risk indicated below (2.5.1.1 to 2.5.1.3). This may be undertaken using clinical judgment, i.e. by recording the risk factors present and noting their number and severity or by employing quantitative risk assessment, using risk algorithms from the Framingham or PROCAM (Figure 2) studies.

2.5.1 Grades of increased risk

2.5.1.1 Small increase in risk

2.5.1.2 Moderate increase in risk

2.5.1.3 High risk

2.5.2 The Risk Calculator

The risk calculator programme (available on the Task Force homepage at: http://www.chd-taskforce.com or http://chd-taskforce.de) may be used to quantify global risk based on the nine independent risk determinants defined in the Münster Heart Study (PROCAM) 15. . This facilitates clinical decision-making as is shown in the following illustrative cases. Patients 1 and 3 are rare in clinical practice but illustrate the concept of global risk; most patients falls between these two extremes.

Example 1. Solitary elevated LDL-cholesterol (180 mg/dL (4.7 mmol/L))
A 45-year-old man with systolic blood pressure 130 mmHg, HDL-cholesterol 49 mg/dL, triglyceride 90 mg/dL, LDL-cholesterol 180 mg/dL, non-smoker, non-diabetic, no family history of myocardial infarction, no history of angina pectoris: the risk of an acute event (fatal or non-fatal MI, sudden cardiac death) in this man, despite a high LDL-cholesterol level, is only 14.1 per 1000 in 8 years, or 0.18% per year, i.e. he falls into the second quintile of risk, i.e. "small increase in risk".

Example2. Multiple risk factors, elevated LDL-cholesterol (180 mg/dL (4.7 mmol/L))<(i>
A 45-year-old man with systolic blood pressure 180 mmHg, HDL-cholesterol 30 mg/dL, triglyceride 250 mg/dL, LDL-cholesterol 180 mg/dL, smoker, non-diabetic, positive family history of MI, positive history of angina pectoris: the risk of an acute event in this man is 625 per 1000 in 8 years or 8% per year, i.e. he falls into highest quintile of risk.

Example 3. Muliple risk factors, normal LDL-cholesterol (100 mg/dL (2.6 mmol/L))
A 45-year-old man with systolic blood pressure 180 mmHg, HDL-cholesterol 30 mg/dL, triglyceride 250 mg/dL, LDL-cholesterol 100 mg/dL, smoker, non-diabetic, family history of MI, positive history of angina pectoris: the risk of an acute event in this man, despite the normal LDL-cholesterol, is 267 per 1000 in 8 years or 3% per year, i.e. he too falls into the highest quintile of risk.